QOL Medical Discontinues Breath Test Sponsorship
In a recent announcement, QOL Medical, LLC has revealed its decision to cease sponsorship of the C-sucrose breath test program, which provided essential services to patients experiencing symptoms of Congenital Sucrase-Isomaltase Deficiency (CSID). This change is set to take effect from March 1, 2025, shifting the responsibility of costs to patients or their insurance plans.
Understanding Congenital Sucrase-Isomaltase Deficiency (CSID)
CSID, a rare condition affecting the digestion of sucrose, is primarily diagnosed through a detailed analysis of the patient's medical history, coupled with various tests. Among these diagnostic methods, the breath test plays a critical role in confirming the presence of the disease.
Transitioning the Breath Test Program
While QOL Medical will no longer fund the breath test, this valuable diagnostic option will still be accessible through Metabolic Solutions. Patients and healthcare providers will need to navigate the new payment structures that come with this transition, ensuring that they remain informed about pricing and reimbursement options.
Contacting Metabolic Solutions
For inquiries related to the C-sucrose breath test, patients and healthcare professionals are encouraged to reach out directly to Metabolic Solutions. This ensures that they have the latest information regarding reimbursement and costs associated with the test.
QOL Medical's Commitment to Patients
Despite discontinuing sponsorship of the breath test program, QOL Medical remains dedicated to enhancing the quality of life for individuals battling rare diseases. The company values the support and understanding of the community during this transitional period.
The Impact of CSID
Individuals diagnosed with CSID face significant challenges in digesting sucrose, which is abundant in everyday foods like sweets, fruits, and baked goods. Symptoms in adults may include chronic abdominal pain, repetitive gas, bloating, and diarrhea, often mistaken for irritable bowel syndrome. In infants, the signs can manifest as explosive diarrhea and issues related to absorption and nutrition.
About QOL Medical, LLC
Founded in 2003, QOL Medical is a pioneering biopharmaceutical organization committed to addressing rare diseases. With a focus on enhancing clinical outcomes and establishing a better quality of life, the company emphasizes the acquisition and commercialization of essential treatments in overlooked markets.
Through its work, QOL Medical aims to shed light on neglected treatments and provide hope to those grappling with rare health challenges. The strategic transition regarding the C-sucrose breath test program emphasizes the company's adaptability and focus on patient needs.
Frequently Asked Questions
1. What is the reason for discontinuing the breath test sponsorship?
QOL Medical is shifting its focus and responsibility regarding the C-sucrose breath test, leading to the discontinuation of sponsorship.
2. Who will provide the C-sucrose breath test after QOL Medical's sponsorship ends?
Patients can still access the breath test through Metabolic Solutions, which will now require payment from patients or insurance.
3. What symptoms are associated with Congenital Sucrase-Isomaltase Deficiency?
Symptoms include abdominal pain, gas, diarrhea, bloating, and in infants, explosive diarrhea and irritability.
4. How can I contact Metabolic Solutions for questions about the breath test?
Metabolic Solutions can be contacted directly for inquiries about the test and reimbursement details.
5. What is QOL Medical's mission?
QOL Medical is dedicated to delivering solutions for rare diseases and improving the quality of life for patients through innovative products.
